Teva Pharmaceutical Industries Limited

Assia Chemical Industries Ltd.

Tamar Nidam

Marioara Mendelovici

Anita Liberman

Judith Aronhime

Claude Singer

Eduard Schwartz

Gideon Pilarsky

Irena Veinberg

Ben-Zion Dolitzky

Nina Finkelstein

Sharona Shachan-Tov

Neomi Gershon

Ariel Mittelman

Rotem Sella-Erez

Evgeni Valdman

Shlomit Wizel

Valerie Niddam-Hildesheim

Anna Balanov

Alexander Mainfeld

Yifat Ronen

Vinod Kumar Kansal

Gideon Pilarski

Maytal Piran

Sigalit Levi

Sharon Avhar-Maydan

Ruth Tenengauzer

Julia Hrakovsky

Natalia Shenkar

Viviana Braude

Harish Ranjan

Eli Lancry

Jonathan Enav

Motti Erlich

Elena Ben Moha-Lerman

Einat Kisin-Finfer

Marina Yarovoy

Omer Malachi

Appu Ekambaram Ponnuswamy

Sunil Rokad

Surat Kiran

Victoria Machtey

Debashish Das

Sagit Azran

Serguei Fine

Greta Sterinbaum

Meital Cohen

Ronen Borochovitch

Abed Masarwa

Solid state forms of Valbenazine, Valbenazine salts, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. Processes for the preparation of Valbenazine and intermediates in the preparation thereof are further described.

Solid state forms of valbenazine

Disclosed are solid state forms of Netarsudil mesylate, processes for preparation thereof, uses thereof, and pharmaceutical compositions thereof.

Solid state forms of netarsudil mesylate

Gabapentin enacarbil was prepared and purified from intermediates such as 1-haloalkyl carbamate or carbonate and diacid acetal skeleton. For example, a 1-haloalkyl carbonate or carbamate was prepared by combining a Cto Calcohol or Cto Cprimary amine, a solvent selected from the group consisting of: acetonitrile, Cto Cketone, Cto Cether, Cto Cester, Cto Chydrocarbon and a combination thereof; a 1-haloalkyl haloformate of the following formula: wherein each X is independently selected from Br, I, or Cl; Ris alkyl or H; and a Cto Ctertiary amine.

Processes for the preparation and purification of gabapentin enacarbil

Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof.

Crystal forms of O-desmethylvenlafaxine fumarate

Provided are processes for the purification of a pure rosuvastatin intermediate by thin film evaporation and chemical method, and conversion of the intermediate to rosuvastatin or salts thereof.

Purification of rosuvatatin intermediate by thin film evaporation and chemical method

Provided are processes for preparing ziprasidone from CEI and BIPT.

Processes for preparation of ziprasidone

The present invention provides a method for preparing a substantially pure lansoprazole containing less than about 0.2% (wt/wt) impurities including sulfone/sulfide derivatives. The present invention also provides a process for recrystallizing lansoprazole to obtain a lansoprazole containing less than about 0.1% (wt/wt) water.

Method for the purification of lansoprazole

The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed.

Sertraline hydrochloride form II and methods for the preparation thereof

The present invention provides improved methods of converting R&#x2014;N-(4-morpholiyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) to the intermediate S&#x2014;N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) that involve the production of fewer by-products than previous methods. The amine (II) may then be converted into linezolid (I) of high chemical purity with respect to the inactive R-enantiomer and bis-linezolid (IV), and is in high yield, without the need for tedious, complicated purification steps, such as chromatography.

Processes for the preparation of linezolid intermediate

The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic form III may be produced by heating sertraline hydrochloride polymorphs V and VI. Sertraline hydrochloride forms V and VI may be produced from either sertraline hydrochloride or sertraline base by crystallization. Sertraline hydrochloride Form VII may be produced by suspending sertraline chloride polymorph V in water, followed by filtration. Sertraline hydrochloride Forms VIII and IX may be produced by suspending sertraline base in water followed by acidification and filtration. Sertraline hydrochloride Form X may be produced by suspending sertraline hydrochloride in benzyl alcohol with heating, followed by filtration.

Sertraline hydrochloride polymorphs

The present invention relates to a novel sulfonation of an intermediate of zonisamide. The sulfonation processes using chlorosulfonic acid as well as acetic anhydride and sulfuric acid in an organic solvent are disclosed. Crystalline forms of benzisoxazole methane sulfonic acid (BOS&#x2014;H) and its salts (BOS&#x2014;Na, BOS&#x2014;Ca, and BOS&#x2014;Ba) and their novel preparation processes are disclosed.

Sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms

Growing community of inventors

Yehud, Israel

Tamar Nidam